Therapeutic inhibitor of vascular smooth muscle cells
First Claim
1. A method for maintaining vessel luminal area following vascular trauma, comprising:
- administering to a mammal an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount that has a minimal effect on protein synthesis and allows for vascular repair.
0 Assignments
0 Petitions
Accused Products
Abstract
Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
605 Citations
17 Claims
-
1. A method for maintaining vessel luminal area following vascular trauma, comprising:
- administering to a mammal an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount that has a minimal effect on protein synthesis and allows for vascular repair.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
9. A method for maintaining vessel luminal area, comprising:
- administering to a mammalian vessel an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount which allows for cellular repair and extracellular matrix production.
- View Dependent Claims (10, 11, 12, 13, 14, 15, 16)
-
17. A method for maintaining vessel luminal area, comprising:
- administering to a mammalian vessel an intravascular stent comprising a sustained release dosage form that inhibits vascular smooth muscle cell proliferation or migration, wherein the sustained release dosage form comprises microparticles, nanoparticles, or a mixture thereof, in a cytostatic amount which allows for cellular repair and extracellular matrix production, wherein the dosage form comprises a cytochalasin or a cytochalasin analog.
Specification